BioSpace News Archive

Proceeds will support development of novel antibody drugs that convert immunologically “cold” tumors into treatable “hot” tumors, with the goal of enhancing effectiveness of cancer immunotherapy

Connect Biopharma Holdings Limited, a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced that the first subject has been dosed in a Phase I trial evaluating CBP-174 in healthy adult subjects.

Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, reports financial results for the first quarter that ended March 31, 2021, along with an update on the company’s key developments, business operations and upcoming milestones.

Immutep Limited, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, announced that Immutep CEO Marc Voigt has been invited to participate in the Jefferies Virtual Healthcare Conference, which is taking place from June 1st to 4th.

Novan, Inc., announced that it has filed a Certificate of Amendment to the Restated Certificate of Incorporation of the Company to implement a one-for-ten reverse split of its issued and outstanding common stock.

CRISPR Therapeutics, a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced that members of its senior management team are scheduled to participate in the following virtual investor conferences in June

Alloy Therapeutics and Pyxis Oncology announced the formation of a joint venture named Kyma Therapeutics to develop immune-modulating antibodies for novel targets in cancer and autoimmune diseases.

aTyr Pharma, Inc., a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, announced the appointment of Sara Zaknoen, M.D., to the company’s Board of Directors.

Unveils development strategy for lanraplenib (LANRA), which will expand addressable patient population for SYK inhibitor portfolio in acute myeloid leukemia (AML); plans to initiate two Phase 1/2 trials in late 2021 and early 2022

PharmaTher Holdings Ltd., a clinical-stage psychedelics biotech company, is pleased to announce that it has filed an application with the U.S. Food and Drug Administration to receive Orphan Drug Designation for ketamine to treat amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease.